To verify whether FXR could reverse the occurrence of CRC, we used FexD, the agonist of FXR, to inhibit intestinal adenoma in APCMin/+ mice, and found that the number and volume of intestinal adenomas were significantly reduced (Figure 7C). Here, NR1H4 is linked to colorectal carcinoma.